A Phase 3 interventional study of Placebo and Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2014-01-29.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 24th largest by enrollment, is the only one that started in 2009, is one of 31 in phase 3, and was the 9th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 33 · Phase 4 13
First in 2006; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 453 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 413 across the 54 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 54 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 14th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2009, is one of 21 in phase 3, and was the 8th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing vortioxetine in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the efficacy of Vortioxetine (5 mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale (HAM-D24) total score after 8 weeks of double-blind treatment in elderly patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical Diagnosis of recurrent Major Depressive Episode (MDE) according the , 4th Edition, Text Revision (DSM-IV-TR) criteria with:
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Vortioxetine (Lu AA21004)
Active reference
Drug: Duloxetine
capsules; daily; orally
encapsulated tablets; daily; orally
Also known as: Brintellix
encapsulated tablets; daily; orally
Also known as: Cymbalta®
Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.
Time frame: Baseline and Week 8
Change From Baseline in HAM-D-24 Total Score After 6 Weeks of Treatment
Time frame: Baseline and Week 6
Change From Baseline in HAM-D-24 Total Score After 4 Weeks of Treatment
Time frame: Baseline and Week 4
Change From Baseline in HAM-D-24 Total Score After 2 Weeks of Treatment
Time frame: Baseline and Week 2
Change From Baseline in HAM-D-24 Total Score After 1 Week of Treatment
Time frame: Baseline and Week 1
Change From Baseline in MADRS Total Score After 8 Weeks of Treatment
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.
Time frame: Baseline and Week 8
Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment
The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.
Time frame: Baseline and Week 8
Change From Baseline in CGI-S Score After 8 Weeks of Treatment
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.
Time frame: Baseline and Week 8
Change in Clinical Status Using CGI-I Score at Week 8
The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.
Time frame: Week 8
Change From Baseline in GDS Total Score After 8 Weeks of Treatment
The Geriatric Depression Scale (GDS) is a patient self-rating scale designed for the screening of depression in the elderly. It has also been validated as a measure of depression severity. The original version consists of 30 questions with a yes/no answer. In this study, the short 15-item version was used. The total score ranges from 0 to 15, with 15 representing maximum severity.
Time frame: Baseline and Week 8
Proportion of Responders at Week 8 (Response Defined as a >=50% Reduction in the HAM-D-24 Total Score)
Time frame: Week 8
Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10)
Time frame: Week 8
Risk of Suicidality Using C-SSRS Scores
The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with sub-questions that assess severity. The tool was administered via an interview with the patient.
Time frame: Up to 8 weeks
Patients were mainly recruited via psychiatric, psycho-geriatric, and geriatric inpatient or outpatient settings.
| Milestone | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Started | 145 | 156 | 151 |
| Completed | 128 | 136 | 128 |
| Not completed | 17 | 20 | 23 |
| Withdrew: Adverse event | 6 | 10 | 15 |
| Withdrew: Lack of efficacy | 7 | 2 | 0 |
| Withdrew: Protocol violation | 3 | 3 | 2 |
| Withdrew: Withdrawal of consent | 1 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Administrative or other reasons | 0 | 3 | 2 |
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.
| units on a scale | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment | -10.3 ± 0.76 | -13.7 ± 0.74 | -15.8 ± 0.75 |
| units on a scale | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Change From Baseline in HAM-D-24 Total Score After 6 Weeks of Treatment | -10.2 ± 0.71 | -12.3 ± 0.69 | -14.4 ± 0.70 |
| units on a scale | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Change From Baseline in HAM-D-24 Total Score After 4 Weeks of Treatment | -8.99 ± 0.64 | -10.1 ± 0.62 | -12.3 ± 0.63 |
| units on a scale | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Change From Baseline in HAM-D-24 Total Score After 2 Weeks of Treatment | -6.66 ± 0.53 | -6.95 ± 0.51 | -7.91 ± 0.52 |
| units on a scale | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Change From Baseline in HAM-D-24 Total Score After 1 Week of Treatment | -3.62 ± 0.41 | -4.04 ± 0.40 | -3.48 ± 0.41 |
The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.
| units on a scale | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Change From Baseline in MADRS Total Score After 8 Weeks of Treatment | -11.2 ± 0.77 | -15.5 ± 0.75 | -18.0 ± 0.76 |
The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.
| units on a scale | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Change From Baseline in HAM-A Total Score After 8 Weeks of Treatment | -5.74 ± 0.55 | -8.09 ± 0.54 | -9.28 ± 0.54 |
The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.
| units on a scale | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Change From Baseline in CGI-S Score After 8 Weeks of Treatment | -1.03 ± 0.11 | -1.63 ± 0.10 | -2.05 ± 0.11 |
The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.
| units on a scale | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Change in Clinical Status Using CGI-I Score at Week 8 | 2.91 ± 0.10 | 2.35 ± 0.09 | 2.07 ± 0.10 |
The Geriatric Depression Scale (GDS) is a patient self-rating scale designed for the screening of depression in the elderly. It has also been validated as a measure of depression severity. The original version consists of 30 questions with a yes/no answer. In this study, the short 15-item version was used. The total score ranges from 0 to 15, with 15 representing maximum severity.
| units on a scale | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Change From Baseline in GDS Total Score After 8 Weeks of Treatment | -0.65 ± 0.17 | -1.08 ± 0.17 | -1.32 ± 0.17 |
| percentage of patients | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Proportion of Responders at Week 8 (Response Defined as a >=50% Reduction in the HAM-D-24 Total Score) | 35 | 53 | 63 |
| percentage of patients | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Proportion of Remitters at Week 8 (Remission Defined as a MADRS Total Score <=10) | 21 | 34 | 47 |
The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with sub-questions that assess severity. The tool was administered via an interview with the patient.
| participants | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| No ideation or behavior | 103 | 107 | 106 |
| Completed Suicide | 0 | 0 | 0 |
| Suicide Attempt | 0 | 0 | 1 |
| Preparatory Actions Toward Imminent Suicidal Behav | 0 | 0 | 0 |
| Suicidal Ideation: Passive | 8 | 14 | 7 |
| Suicidal Ideation: Active / Nonspecific | 3 | 0 | 0 |
| Suicidal Ideation: Active / Method, but no intent | 0 | 0 | 0 |
| Suicidal Ideation: Active / Method and intent, but | 0 | 0 | 0 |
| Suicidal Ideation: Active / Method, intent, and pl | 0 | 0 | 0 |
| Self-Injurious Behavior Without Suicidal Intent | 0 | 0 | 0 |
Collected over Serious Adverse Events: 8-week double-blind treatment period and 4-week safety follow-up period Other Adverse Events: 8-week double-blind treatment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 4/145 (2.8%) | 63/145 (43.4%) |
| Vortioxetine 5 mg | — | 1/156 (0.6%) | 72/156 (46.2%) |
| Duloxetine 60 mg | — | 1/151 (0.7%) | 104/151 (68.9%) |
| Event | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/55 | 0/49 | 1/51 |
| Hip fractureInjury, poisoning and procedural complications | 1/145 | 0/156 | 0/151 |
| Bile duct cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/145 | 0/156 | 0/151 |
| Transient ischaemic attackNervous system disorders | 1/145 | 0/156 | 0/151 |
| DepressionPsychiatric disorders | 1/145 | 0/156 | 0/151 |
| Major depressionPsychiatric disorders | 0/145 | 1/156 | 0/151 |
| Event | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 12/145 | 34/156 | 50/151 |
| Dry mouthGastrointestinal disorders | 7/145 | 10/156 | 33/151 |
| HeadacheNervous system disorders | 25/145 | 18/156 | 18/151 |
| ConstipationGastrointestinal disorders | 6/145 | 10/156 | 21/151 |
| FatigueGeneral disorders | 5/145 | 11/156 | 16/151 |
| SomnolenceNervous system disorders | 3/145 | 4/156 | 16/151 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 4/145 | 6/156 | 16/151 |
| DiarrhoeaGastrointestinal disorders | 10/145 | 8/156 | 14/151 |
| DizzinessNervous system disorders | 10/145 | 14/156 | 14/151 |
| Ejaculation delayedReproductive system and breast disorders | 0/55 | 0/49 | 3/51 |
Full-analysis set (FAS) - all patients in the all-patients-treated set (APTS) who had at least one valid post-baseline assessment of the primary efficacy variable
| Age, Continuous(years) | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|
| Mean | 70.3 ± 4.4 | 70.5 ± 4.8 | 70.9 ± 5.5 | 70.6 ± 4.9 |
| Sex: Female, Male(Participants) | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|
| Female | 90 | 107 | 100 | 297 |
| Male | 55 | 49 | 51 | 155 |
| HAM-D-24(units on a scale) | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|
| Mean | 29.4 ± 5.1 | 29.2 ± 5.0 | 28.5 ± 4.9 | 29.0 ± 5.0 |
| MADRS(units on a scale) | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|
| Mean | 30.3 ± 3.2 | 30.7 ± 3.6 | 30.4 ± 3.1 | 30.5 ± 3.3 |
| HAM-A(units on a scale) | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|
| Mean | 19.5 ± 5.7 | 19.9 ± 5.8 | 19.2 ± 6.5 | 19.5 ± 6.0 |
| CGI-S(units on a scale) | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|
| Mean | 4.7 ± 0.7 | 4.8 ± 0.7 | 4.7 ± 0.8 | 4.7 ± 0.7 |
| GDS(units on a scale) | Placebo | Vortioxetine 5 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|
| Mean | 7.7 ± 2.0 | 7.4 ± 2.2 | 7.7 ± 2.3 | 7.6 ± 2.2 |
No study locations are listed for this record.
The record gives a start of Jan 2009, a primary completion of Feb 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine